omniture
logo
Search
Ascletis Pharma Inc./歌礼生物科技（杭州)有限公司
Media Room

Latest News

rss

Ascletis Announces Completion of the Bridging Study and Initiation of Phase II Trial of FXR Agonist ASC42 in China for Chronic Hepatitis B Indication

HANGZHOU and SHAOXING, China, Aug. 25, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) annou...

2021-08-25 08:30 4540

Ascletis' Partner Sagimet Dosed First Patient in FASCINATE-2 Phase IIb Trial in NASH Patients with Moderate to Advanced Fibrosis

HANGZHOU and SHAOXING, China, Aug. 16, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) today ...

2021-08-16 21:30 4367

China NMPA Approves Phase II Clinical Trial of ASC40 for the Treatment of Patients with Acne

HANGZHOU and SHAOXING, China, Aug. 9, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) t...

2021-08-09 08:30 4530

Ascletis Announces Completion of 149 Patient Enrollment and Positive Interim Results of Phase IIb Chronic Hepatitis B Study in China for its Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)

* HBsAg reduction was observed in the 1 mg/kg ASC22 once every two weeks plus nucleos(t)ide analo...

2021-07-28 08:30 3652

China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma

HANGZHOU, China and SHAOXING, China, July 22, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code:...

2021-07-22 08:30 3896

Ascletis Announces Dosing of the First Cohort of Healthy Subjects in the FXR Agonist ASC42 Bridging Study for Chronic Hepatitis B Indication in China

--This bridging study to select doses for the Phase II trial in China in patients with chronic hep...

2021-07-13 08:30 3777

Gannex Announces Positive Topline Results of the U.S. Phase I Trial of NASH Drug ASC42, an FXR Agonist

SHANGHAI, June 16, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2021-06-16 21:00 4074

Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication

HANGZHOU, China and SHAOXING, China, June 7, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672)...

2021-06-07 08:30 4196

Gannex Received China IND Approval of Its FXR Agonist ASC42 for NASH Indication

SHANGHAI, May 27, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX...

2021-05-27 08:30 3923
1 ... 45678